ALK and lung carcinoma: A systematic review by Liu et al. of 20 retrospective studies showed that anaplastic lymphoma kinase (ALK) mutation has a higher risk of VTE than epidermal growth factor receptor (EGFR) mutation [29], while another systematic review by Alexander et al. reported that EGFR mutation was the strongest risk factor for VTE in patients with lung cancer [30].